Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life

AbbVie

Status: Completed

Conditions: Psoriasis

Study type: Observational

Funder types: Industry

Identifiers

NCT01169987

P12-129

Details and patient eligibility

About

This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years. Reasons for interrupting or permanently discontinuing Humira therapy and reasons for restarting Humira therapy will be noted. An evaluation will be performed of the effect of the disease on quality of life and work productivity.

Enrollment: 191 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients > or = 18 years
• Patient with chronic plaque psoriasis
• Patient newly initiated on Humira
• Patient compliant with Humira Summary of Product Characteristics
• Patient compliant with Belgian reimbursement criteria of Humira in plaque psoriasis
• Patient has signed informed consent

Exclusion criteria

• Patients having any of the contraindications mentioned in the Summary of Product Characteristics Humira
• Patients not willing to sign informed consent

Trial design

191 participants in 1 patient group

Participants Treated with Adalimumab

Description:

Participants with chronic plaque psoriasis in whom adalimumab (Humira) treatment is initiated. All medications will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.